In short
This article discusses a clinical trial investigating the use of Ipratropium Bromide Monohydrate in combination with salbutamol for treating moderate asthma attacks in children. The study aims to determine if salbutamol alone is as effective as the combination therapy in managing acute asthma exacerbations in pediatric emergency departments.
At a glance
- Study Type
- Phase III, double-blind, randomized, controlled, non-inferiority clinical trial
- Main Objective
- Compare salbutamol alone to salbutamol plus Ipratropium Bromide in treating moderate asthma attacks in children
- Primary Endpoint
- Reduction in hospital admission rates
- Participant Age Range
- 1 to 18 years old
- Study Duration
- Approximately 24 months (12 months for patient recruitment)
- Treatment Comparison
- Salbutamol monotherapy vs. Salbutamol + Ipratropium Bromide combination
- Setting
- Pediatric Emergency Departments
What is Ipratropium Bromide Monohydrate?
Ipratropium Bromide Monohydrate is a medication used to treat respiratory conditions, particularly asthma. It belongs to a class of drugs known as anticholinergics or antimuscarinic bronchodilators. These medications work by relaxing and opening up the airways in the lungs, making it easier to breathe.
Medical Uses
The primary use of Ipratropium Bromide Monohydrate is in the treatment of asthma, especially during acute exacerbations or attacks. An asthma attack is a sudden worsening of asthma symptoms that can make breathing difficult. In the clinical trial described, the medication is being studied for its effectiveness in treating moderate acute asthmatic exacerbations in children.
How is it Administered?
Ipratropium Bromide Monohydrate is typically administered through inhalation. The specific product mentioned in the clinical trial is called "ATROALDO," which is a pressurized inhalation solution. This means the medication is delivered as a fine mist that you breathe in, allowing it to reach directly into your lungs where it's needed.
Current Clinical Trial
A Phase III clinical trial is currently being conducted to evaluate the effectiveness of Ipratropium Bromide in combination with another medication called salbutamol. Here are the key points about this study:
- It's a double-blind, randomized, controlled, non-inferiority trial. This means neither the patients nor the doctors know who's receiving which treatment, and it's designed to see if one treatment is not worse than another.
- The study aims to compare salbutamol alone versus salbutamol plus Ipratropium Bromide in treating moderate asthma attacks in children.
- The main goal is to determine if using salbutamol alone is not inferior to using it in combination with Ipratropium Bromide in reducing hospital admissions for children with moderate asthma attacks.
- The study includes children from 1 to 18 years old with moderate asthma exacerbations.
Dosage Information
According to the clinical trial information, the maximum daily dose of Ipratropium Bromide Monohydrate is 800 micrograms. However, it's important to note that this is the maximum dose used in the study and may not reflect the typical prescribed dose. Always follow your doctor's instructions regarding medication dosage.
Precautions and Contraindications
The clinical trial information provides some insights into when Ipratropium Bromide should not be used. These situations include:
- Patients with a history of hypersensitivity (allergic reaction) to Ipratropium Bromide
- Individuals with narrow-angle glaucoma (an eye condition)
- Patients with pre-existing obstruction of the urinary outflow tract
- Pregnant or breastfeeding women
- Patients with certain neuromuscular diseases affecting respiratory capacity
- Individuals with specific chronic respiratory conditions like cystic fibrosis
It's crucial to inform your healthcare provider about all your medical conditions and medications before starting treatment with Ipratropium Bromide Monohydrate.